[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606786":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":38,"responsibleParty":55,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intermittent pyrotinib","EXPERIMENTAL","Intermittent use of pyrotinib, 14 days on and 7 days of, every 21 days",[13],"Drug: Pyrotinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Continuous pyroitnib","ACTIVE_COMPARATOR","oral pyrotinib qd",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Pyrotinib","anti-HER2 tyrosine kinase inhibitor",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":25,"email":35},"CONTACT","86(21)68385569","yinwenjin@renji.com",{"name":37,"role":33,"phone":25,"phoneExt":25,"email":25},"Yin",[39],{"facility":40,"status":41,"city":42,"state":25,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":54,"role":33,"phone":34,"phoneExt":25,"email":35},"Wenjin Yin",{"type":56,"investigatorFullName":54,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Deputy Chief of Breast Surgery Department","100606786","phase-2-continuous-or-intermittent-pyrotinib-for-her2-positive-advanced-breast-cancer-100606786",false,"NCT07180082","Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer","Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer: a Prospective, Randomized, Controlled, Multicentre Clinical Trial","CORIN-PYRA","Inclusion Criteria:\n\n* Age≥18 years old\n* Pathologically confirmed advanced or locally advanced breast cancer not amenable to curative surgery\n* Pathologically confirmed HER2+ at least once for either primary or metastatic lesion\n* Previously treated with any number of lines for advanced disease and eligible for a pyrotinib-containing regimen at the discretion of physician\n* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* During pregnancy and lactation\n* Difficulties with pyrotinib administration or absorption","ALL","18 Years",{"count":69,"type":70},186,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.",[76],"Advanced Breast Cancer","2025-11-16",{"date":79,"type":80},"2025-11-18","ACTUAL",{"date":82,"type":80},"2025-08-28",{"date":84,"type":70},"2029-09",{"name":54,"class":6},1]